Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 31, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital movements.
- Shares Repurchased: 1,150,000 ordinary shares.
- Repurchase Price: 1,284.76 pence per share.
- Treasury Shares Held: 377,027,158 shares (representing 6.68% of total voting rights).
- Shares in Issue: 5,645,342,189 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 1,150,000 shares on August 31, 2007. These shares are intended to be held in Treasury. Consequently, the total number of shares in issue (excluding Treasury) remains 5,645,342,189, which serves as the denominator for shareholder notification calculations under the Financial Services Authority's Disclosure and Transparency Rules.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Checklist
- Verify the total number of shares in issue (5,645,342,189) for compliance with disclosure thresholds.
- Confirm the updated Treasury share count (377,027,158) and its percentage of voting rights (6.68%).
- Review the specific repurchase price (1,284.76 pence) against market prices on August 31, 2007.
- Note that this filing does not contain financial results; refer to Form 20-F or interim reports for revenue and earnings data.